Back to the Top
Hello dear all,
Does anyone know a source/site where people maintain an comprehensive
updated list on CYP450 interactions?
Erik Pomp,
a DI-pharmacist
Back to the Top
Erik:
Check Dave Flockhart's Table at
http://www.dml.georgetown.edu/depts/pharmacology/davetab.html
Tayo Fadiran
Office of Clinical Pharmacology,
HFD-860, FDA.
Back to the Top
Eric,
Let's look at the article of Elizabeth Landrum Michalets " Reviews of
Therapeutics" in Pharmacotherapy 1998 ; 18 (1) : 84-112 called Update :
clinically significant cytochrome P450 Drug Interactions.
Caroline MAJER
PharmD
cm76381.-a-.ggr.co.uk
Back to the Top
From: "Tata, Prasad"
To: "'PharmPK.-a-.pharm.cpb.uokhsc.edu'"
Subject: RE: PharmPK CYP450 interactions
Date: Wed, 29 Apr 1998 16:26:08 -0400
MIME-Version: 1.0
You can refer to the book Cytochrome P-450, structure, Mechanism and
Biochemistry - Paul R. Oritz and Montellano (ISBN 0-306-45141-7). This is a
book that deals with most of your questions
Other reference is Clinical P{Pharmacokinetics - 1995, 29(S1), 10-52.
There is another reference in Die Pharmazie( German Journal) in 1993 or 1994
which is a review article ran as two parts listing comprehensive list of
drug-drug interactions.
Hope this helps.
---
Date: Wed, 29 Apr 1998 14:30:03 -0600
X-Sender: cathy.aaa.otc.isu.edu
Mime-Version: 1.0
To: PharmPK.aaa.pharm.cpb.uokhsc.edu
From: Cathy Heyneman
Subject: Re: PharmPK CYP450 interactions
Hi Erik!
There was an excellent, very detailed review article published in
Pharmacotherapy within the last three months. If you need more info than
that, I can do some digging.
Good luck!
Cath Heyneman
-another DI pharmacist :)
-----------------------------
Catherine Heyneman, Pharm.D. Phone: (208) 236-2743
ISU College of Pharmacy FAX: (208) 236-4305
Pocatello, ID 83209 E-Mail: cathy.-a-.otc.isu.edu
---
Precedence: first-class
Date: Wed, 29 Apr 1998 16:54:19 -0400 (EDT)
From: Juliana Chan
X-Sender: bochan.-a-.gorf.rs.itd.umich.edu
To: PharmPK.-at-.pharm.cpb.uokhsc.edu
cc: Multiple recipients of PharmPK - Sent by
Subject: Re: PharmPK CYP450 interactions
MIME-Version: 1.0
There is a good review article recently published (1998) in
"Pharmacotherapy".
It highlights all you need to know about P450 interactions.
Juliana Chan, Pharm.D
Pharmacy Practice Resident
University of Michigan
Department of Pharmacy
1500 East Medical Center Drive.
734-936-8210
---
From: "Joseph Balthasar"
To:
Subject: Re: PharmPK CYP450 interactions
Date: Wed, 29 Apr 1998 15:45:53 -0600
X-Priority: 3
MIME-Version: 1.0
Dear Erik:
Check out David Flockhart's CYP interaction list at the web site below:
http://www.dml.georgetown.edu/depts/pharmacology/davetab.html
************************************************************
Joseph P. Balthasar, PhD
Assistant Professor
University of Utah
Department of Pharmaceutics
and Pharmaceutical Chemistry
421 Wakara Way, Suite 316
Salt Lake City, Utah 84108
Telephone: 801-585-5958
Fax: 801-585-3614
************************************************************
---
Date: Wed, 29 Apr 1998 16:21:25 -0700
From: "Carol A. Roby, PharmD/MS"
Reply-To: croby.at.pharmacy2.ab.umd.edu
Organization: University of Maryland at Baltimore
MIME-Version: 1.0
To: PharmPK.at.pharm.cpb.uokhsc.edu
Subject: Re: PharmPK CYP450 interactions
The ACCP site has a cyp450 interaction table you can print out. Hope
this helps.
Carol
PS, the url is www. accp.com :-)
---
From: "Chad Shedron"
To:
Subject: Re: PharmPK CYP450 interactions
Date: Wed, 29 Apr 1998 19:55:27 -0500
X-Priority: 3
MIME-Version: 1.0
An excellent resource is the American College of Clinical Pharmacy (ACCP)
homepage .at. www.accp.com. Within this page is a chart detailing CYP450
interactions with many helpful references.
---
Date: Thu, 30 Apr 1998 06:07:28 -0400 (EDT)
X-Sender: jasmith.-at-.pop.cc.nih.gov
Mime-Version: 1.0
To: PharmPK.aaa.pharm.cpb.uokhsc.edu
From: Judith Smith
Subject: Re: PharmPK CYP450 interactions
The most recent I have seen was published in Pharmacotherapy 1998;18(1) 84-112.
Judith A. Smith, Pharm.D.
Oncology Pharmacy Practice Resident
National Institutes of Health
Back to the Top
Hello Erik,
If you are familiar with Micromedex(R), their DrugReax(R) system or their
Drug Evaluations are rather good interaction databases - and not only CYP
interactions are mentioned. Another source is Hansten's Drug Interactions
and Updates. I am not familiar with a specific CYP interaction database,
but this would be of great interest. I would like to mention that
interactions should be of clinical relevance, and in vitro livermicrosome
interactions or predicted interactions 8from knowledge of CYP metabolism)
should NOT be regarded as drug-drug interactions until proven in clinical
studies.
Sincerely,
Thomas Senderovitz, MD
Unit of Clinical Pharmacology
University of Copenhagen
Bispebjerg Hospital
DK-2400 Copenhagen NV
Denmark
E-mail: senderovitz.aaa.dadlnet.dk
Back to the Top
Dear Thomas Senderovitz
You wrote:
"I am not familiar with a specific CYP interaction database,
but this would be of great interest. I would like to mention that
interactions should be of clinical relevance, and in vitro livermicrosome
interactions or predicted interactions 8from knowledge of CYP metabolism)
should NOT be regarded as drug-drug interactions until proven in clinical
studies."
I agree that the clinical relevance of drug interactions needs to be
established before they are acted upon clinically, however I disagree that
knowledge from in vitro or theoretical interactions should be disregarded
as you suggest until it has been proven clinically. These are two
different concepts the first suggests that only those interactions that are
theoretically important should be acted upon (eg terfenadine and
ketoconazole). The second suggests that you should ignore any potential
interaction until it has been proven (eg would a prescription for
terfenadine and a protease inhibitor be considered safe?).
In my experience by the time the interaction has occurred clinically you
have missed the boat (in a manner of speaking). I strongly believe that it
is important to have a working qualitative knowledge of potential drug
interactions that when mixed with a level of clinical suspicion allows
appropriate decisions to be made.
This does not discount the need and obvious importance of rigorous clinical
studies.
Regards
Steve Duffull
PS A good review of CYP enzymes/interactions etc is available in J
Pharmacokinet Biopharm 1996;24
============
Stephen B Duffull
School of Pharmacy
Manchester University
Manchester M13 9PL
ENGLAND
Ph + 44 161 275 2355
Fax + 44 161 275 2396
Back to the Top
From: Nick Holford
Sender: nhol004.at.auckland.ac.nz
Reply-To: n.holford.at.auckland.ac.nz
To: PharmPK.aaa.pharm.cpb.uokhsc.edu
Subject: PharmPK Re: Sv: CYP450 interactions
Date: Fri, 1 May 1998 16:41:53 -0400 (Eastern Daylight Time)
Priority: NORMAL
X-Authentication: none
MIME-Version: 1.0
On Fri, 1 May 1998 10:06:00 -0500 Stephen Duffullwrote:
Thomas Senderovitz wrote:
> should NOT be regarded as drug-drug interactions until proven in clinical
> studies."
Steve said:
> I strongly believe that it
> is important to have a working qualitative knowledge of potential drug
> interactions that when mixed with a level of clinical suspicion allows
> appropriate decisions to be made.
> This does not discount the need and obvious importance of rigorous clinica=
l
> studies.
Long live Steve's Bayesian/science viewpoint!
Down with those empiricists, frequentists and intention-to-treaters!
--
Nick Holford, Center for Drug Development Science
Georgetown University, 3900 Reservoir Rd NW, DC 20007-2197
email:n.holford.-a-.auckland.ac.nz tel:(202)687-1618 fax:687-0193
http://www.phm.auckland.ac.nz/Staff/NHolford/nholford.htm
---
Reply-To: "Thomas Senderovitz"
From: "Thomas Senderovitz"
To: "PHARM PK"
Subject: Sv: PharmPK Re: Sv: CYP450 interactions
Date: Sat, 2 May 1998 10:19:47 +0200
MIME-Version: 1.0
X-Priority: 3
Dear Stephen and others,
I didn't actually write thant one should DISREGARD in vitro results - they
can of course generate ideas for clinical studies. But the problem is still
whether you can extraploate from in vitro (or from animals) to the clinical
situation. We can get a hint, yes, but often we have been mislead by simple
extrapolation. The human body and clinical set-up is much more complicated
than a simple CYP.
On the other hand, potential dangerous interactions shown by in vitro
studies should be monitored carefully, but I still believe that firm
conclusions should be made on clinical proof (no rules without exceptions,
of course). So, actually Stephen, I think we totally agree.
Sincerely,
Thomas Senderovitz, MD.
E-mail: senderovitz.aaa.dadlnet.dk
---
From: Erik Fred Oscar Pomp
To: "'PharmPK.-at-.pharm.cpb.uokhsc.edu'"
Subject: SV: PharmPK Sv: CYP450 interactions
Date: Mon, 4 May 1998 10:01:49 +0200
MIME-Version: 1.0
Thanks,
I am familiar with all the sources you mentioned. I share your opinion
on drug interactions, but now and then we need rather theoretical
explanations in our work (regional drug information centre, Haukeland
sykehus, Bergen, Norway).
Kind regards
Erik Pomp
---
From: Olof.Borga.-a-.draco.se.astra.com
To: PharmPK.at.pharm.cpb.uokhsc.edu
Subject: RE: PharmPK Re: CYP450 interactions
Date: Mon, 4 May 1998 13:05:41 +0200
Mime-Version: 1.0
Tayo, thank you for the valuable contribution.
Olof Borg=E5, Ph.D.
Pharmacokinetic Expert
Kinetics and Metabolism
Preclinical R&D
Astra Draco AB, P.O. Box 34, S-221 00 Lund, Sweden
Tel: +46 46 33 60 00 Direct: +46 46 33 68 75
Fax: +46 46 33 66 66 Direct: +46 46 33 71 64
e-mail: olof.borga.at.draco.se.astra.com
Back to the Top
D.J. Touw. Clinical implications of genetic polymorphism and drug
interactions mediated by cytochrome P-450 enzymes. Drug Metabolism and
Drug Interactions, 1997; 14 (no 2): 55-82.
Back to the Top
Additional source for CYP-450 enzyme substracts
The American College of Clinical Pharmacy maintains a web page
containing a list of P-450 substrates that can be downloaded.
Referecnces are included.
Back to the Top
David,
could you please forward the URL of that web-page, thank you.
Bernhard J. Ladstetter, Ph.D.
Institute of Pharmacokinetics and Metabolism
Merck KGaA
---
From: Han_Waterbeemd.-at-.sandwich.pfizer.com
Mime-Version: 1.0
Date: Tue, 12 May 1998 15:49:19 +0100
Subject: Re: PharmPK Re: CYP450 interactions
To: PharmPK.aaa.pharm.cpb.uokhsc.edu
What is the URL of this site?
---
[I had a look around the ACCP site and couldn't find the page - db]
Back to the Top
Greetings, all!
If you point your browser to www.accp.com, click on the icon for "other
services" at the bottom of the menu. It will send you to a link that
takes you to downloadable files which contains the data and the
bibliography. If you have the Adobe Acrobat reader, it will put the data
on your screen and make it printable.
I hope this information proves useful.
With best regards,
Vince Pearson, Pharm.D.,BCPS
Clincal Coordinator, Drug Information
The Johns Hopkins Hospital
Baltimore, Maryland USA
Back to the Top
[A few replies to the same URL - You need Adobe Reader to see the pages - db]
From: "David Nix"
To: PharmPK.at.pharm.cpb.uokhsc.edu
Date: Tue, 12 May 1998 13:47:55 MST7
Subject: Re: PharmPK Re: CYP450 interactions
Priority: normal
My appologies - I intended to provide the URL address, but for some
reason it was left off. Here it is:
http://www.accp.com/p450.html
---
X-Sender: gilman#mail.simulations-plus.com.-at-.192.168.0.1
Date: Tue, 12 May 1998 16:55:20 -0700
To: PharmPK.at.pharm.cpb.uokhsc.edu
From: Thomas Gilman
Subject: Re: PharmPK Re: CYP450 interactions
Mime-Version: 1.0
David, the ACCP Drugs and Cytochrome P450 Isoenzymes URL is
http://www.accp.com/p450.html
---
Date: Wed, 13 May 1998 09:59:31 -0400 (EDT)
From: VINCENT EARL PEARSON
To: PharmPK.at.pharm.cpb.uokhsc.edu
cc: Multiple recipients of PharmPK - Sent by
Subject: Re: PharmPK Re: CYP450 interactions
MIME-Version: 1.0
Greetings, all!
If you point your browser to www.accp.com, click on the icon for "other
services" at the bottom of the menu. It will send you to a link that
takes you to downloadable files which contains the data and the
bibliography. If you have the Adobe Acrobat reader, it will put the data
on your screen and make it printable.
I hope this information proves useful.
With best regards,
Vince Pearson, Pharm.D.,BCPS
Clincal Coordinator, Drug Information
The Johns Hopkins Hospital
Baltimore, Maryland USA
---
Date: Wed, 13 May 1998 10:14 -0600
From: "Fiona Stavros"
To: PharmPK.-at-.pharm.cpb.uokhsc.edu
Subject: Re: PharmPK Re: CYP450 interactions
Try http://www.accp.com/news96012.html and click on "other services" on
their home
page.
Fiona
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)